Product Description
CUD005 injection is based on the patient's autoimmune cells, which are differentiated into mature and stable individualized anti-fibrotic macrophages, which can degrade the extracellular matrix and reduce liver scarring by secreting various matrix metalloproteinases. Furthermore, CUD005 injection can release anti-inflammatory factors, thereby inhibiting the occurrence of inflammatory reactions, improving the microenvironment of liver inflammation, and slowing the development of the condition. (Sourced from: https://news.futunn.com/en/post/40095942/laimei-pharmaceutical-300006-sz-cud005-injection-approved-to-conduct-clinical?level=1&data_ticket=1718216802760346)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sichuan Kangdesai Medical Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20242081 | P1 |
Unknown |
Liver Cirrhosis |
None |